This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Atreca Future Growth
Future criteria checks 0/6
Atreca is forecast to grow earnings at 8.9% per annum. EPS is expected to grow by 25.8% per annum.
Key information
8.9%
Earnings growth rate
25.8%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 23 Feb 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -52 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -48 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -43 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -80 | N/A | N/A | 2 |
| 9/30/2023 | N/A | -98 | -65 | -65 | N/A |
| 6/30/2023 | N/A | -85 | -65 | -64 | N/A |
| 3/31/2023 | N/A | -93 | -71 | -70 | N/A |
| 12/31/2022 | N/A | -97 | -82 | -81 | N/A |
| 9/30/2022 | N/A | -105 | -86 | -81 | N/A |
| 6/30/2022 | N/A | -110 | -88 | -81 | N/A |
| 3/31/2022 | N/A | -108 | -93 | -69 | N/A |
| 12/31/2021 | N/A | -109 | -96 | -61 | N/A |
| 9/30/2021 | N/A | -103 | -96 | -63 | N/A |
| 6/30/2021 | N/A | -98 | -93 | -62 | N/A |
| 3/31/2021 | N/A | -92 | -82 | -66 | N/A |
| 12/31/2020 | N/A | -86 | -72 | -67 | N/A |
| 9/30/2020 | N/A | -83 | -70 | -65 | N/A |
| 6/30/2020 | N/A | -76 | -71 | -65 | N/A |
| 3/31/2020 | N/A | -74 | -67 | -63 | N/A |
| 12/31/2019 | N/A | -67 | -62 | -59 | N/A |
| 9/30/2019 | N/A | -59 | -56 | -53 | N/A |
| 6/30/2019 | N/A | -53 | -47 | -45 | N/A |
| 3/31/2019 | N/A | -44 | -41 | -40 | N/A |
| 12/31/2018 | N/A | -38 | -36 | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0C1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0C1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0C1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 0C1's revenue is forecast to grow faster than the German market.
High Growth Revenue: 0C1 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0C1's Return on Equity is forecast to be high in 3 years time